Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer

Online download statistics by month:

Online download statistics by month: July 2022 to August 2024

	Abstract	Full	Pdf
Jul 2022	1012	1030	390
Aug 2022	528	542	178
Sep 2022	362	369	305
Oct 2022	370	380	137
Nov 2022	270	272	136
Dec 2022	213	213	93
Jan 2023	219	220	64
Feb 2023	254	256	117
Mar 2023	250	254	93
Apr 2023	201	205	66
May 2023	195	202	95
Jun 2023	221	226	75
Jul 2023	252	252	70
Aug 2023	252	252	65
Sep 2023	254	260	64
Oct 2023	325	330	87
Nov 2023	319	321	108
Dec 2023	329	337	112
Jan 2024	136	137	140
Feb 2024	179	183	70
Mar 2024	459	463	256
Apr 2024	357	358	93
May 2024	143	143	53
Jun 2024	154	154	56
Jul 2024	311	311	75
Aug 2024	296	294	53
Total	7861	7964	3051